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Abstract
Background: Difficulty performing more than one task at a time (dual tasking) is a common and disabling
problem experienced by people with Parkinson disease (PD). If asked to perform another task when walking,
people with PD often take shorter steps or walk more slowly. Currently there is uncertainty about whether
clinicians should teach people with PD to avoid dual tasking or whether they should encourage them to practice
dual tasking with the hope that practice will lead to enhanced performance. This study will address this issue by
comparing single to dual task gait training.
Methods and design: A prospective randomised clinical trial is being conducted. Sixty participants with idiopathic
PD will be recruited, provided they score I-IV on the modified Hoehn and Yahr (1967) scale, and fulfil other
inclusion criteria. Participants will be randomly allocated to either a single or dual task gait training group. Both
groups will receive 12 hours of walking training over 4 weeks. The single task group will undertake gait training
with cueing strategies to increase step length. The dual task group will train to improve step length when walking
and performing a variety of added tasks. Both groups will receive a tailored home program for 6 months. Blinded
assessors will conduct four assessments: two baseline assessments, one post intervention and one at 6 months
follow-up. The primary outcome measure will be step length when dual tasking over 8 m. Secondary outcome
measures include: spatiotemporal gait parameters when walking under single and dual task conditions, measures
of executive function, the timed up and go test, measures of community mobility, and quality of life. All analyses
will be based on intention to treat principle.
Discussion: This trial will examine the immediate and longer term effect of dual task walking training as compared
to single task training in people with idiopathic PD, at the impairment, activity, and participation levels. It has the
potential to identify a new intervention that may improve and maintain walking beyond the laboratory. The results
of this trial will provide guidance for clinicians in the development of walking training programs for people with PD.
Trial Registration: ACTRN12609000791235
Background
Over 4 million people worldwide are estimated to be
diagnosed with Parkinson disease (PD), with this pro-
jected to double within the next 20 years [1]. More than
half of community dwelling adults living with PD experi-
ence gait disturbances that are associated with increased
disease severity, disability, poor quality of life [2] and
caregiver strain[3,4]. Falls are a common complication of
PD, with between 50 and 68% of people with PD falling
each year [5-8], with most falls reported to occur when
walking [9]. Medications such as levodopa, provide the
cornerstone of treatment of gait disturbances in PD,
however these become less effective over time for some
symptoms of PD including gait disturbance. There is
growing evidence that strategy training, whereby internal
or external cues are used to direct a person’s attention to
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normalise their gait deficits, is effective in augmenting
drug therapy to improve gait in the short term [10].
Internal cues involve the person directing their attention
to consciously think of improving the deficit (e.g. think-
ing ‘big steps’). External cues aim to normalise the gait
deficit and often include verbal cues (e.g. saying ‘big
steps’), visual cues (e.g. lines on the floor at the desired
step length) [11], or auditory cues (e.g. metronome to
normalise cadence) [12]. The majority of this evidence is
based on laboratory-based training [10] with low sample
sizes, and measures of immediate effects of therapy. The
longer term effect of strategy training is not yet clear.
For gait to be functional in daily life both within the
community and home, people need to be able to dual
task. This could involve thinking when walking or main-
taining balance when holding an object. It is well known
that performing an added task interferes with postural
stability in older adults (termed dual task interference)
[13], particularly in those adults with impaired balance
[14-16].
It is well established that when asked to perform a con-
current task when walking, people with PD demonstrate
reduced gait velocity, step length [11,17-20], increased
stride to stride variability [21] and more freezing episodes
[22,23] than when walking alone. These gait disturbances
are also known falls risk factors [6]. An underlying ratio-
nale proposed for dual task interference in PD is that
when required to perform two tasks at the same time,
one runs through the frontal cortical regions and is
under conscious control while the other is controlled by
the defective basal ganglia. The task controlled by the
frontal lobes is typically performed with normal speed
and amplitude whereas the task controlled by the basal
ganglia may show errors and be under-scaled in speed,
amplitude and force [11].
Despite laboratory studies showing the serious effects
of dual task interference on the spatiotemporal gait vari-
ables in PD, to date there have been few investigations
of the effects of training on dual task interference during
locomotion in PD. A pilot study of 90 minutes of multi-
ple task training in 5 people with mild to moderate
Parkinson Disease reported that participants reported
low levels of fatigue, difficulty and anxiety and high
levels of confidence [24]. A recent study has also
demonstrated that people with PD can improve their
ability to dual task when walking with training [25],
however it only investigated the immediate effects of a
20 minute gait training session.
The primary aim of this randomised controlled trial
(RCT) is to determine the short and longer-term effects
of dual-task training compared to single task training
during gait on walking performance when dual tasking
in people with PD. In addition, we will determine the
impact of the training programs on gait impairment,




A prospective, single blinded two group randomised
clinical trial with 6 month follow up of 60 people with
PD living in the community setting will be conducted
(Figure 1).
Location and setting
We plan to recruit 60 people with PD, through Parkinson’s
Queensland Inc., a support organisation for people with
PD, neurologists who specialise in Movement Disorders,
and from the Queensland Parkinson’s Project - a research
study register of over 3000 community dwelling Queens-
landers, recruited since 2005, who have agreed to partici-
pate in research into Parkinson’s Disease and related
disorders. Assessment will be undertaken at the Princess
Alexandra Hospital, Brisbane, and training undertaken at
St Andrew’s War Memorial Private Hospital, Brisbane.
Population
To be included in the study participants must meet the
following criteria: (i) aged 18 years or older; (ii) a diag-
nosis of idiopathic PD using the UK Brain Bank criteria;
(iii) able to walk 100 m independently with or without
gait aids; (iv) rated stage I-IV on Hoehn and Yahr
Assessed for eligibility
Baseline 1 - measurement
Randomization
Baseline 2 - measurement
Allocation to groups
Single task gait training Dual task gait training
Post intervention measurement
6-month follow up measurement
Figure 1 Trial design.
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disability scale [26]; and (v) report reduced step length
or slowed gait speed, confirmed by clinical examination.
Participants will be excluded if they have neurological
conditions other than PD, musculoskeletal or cardiopul-
monary conditions that affect the ability to safely walk,
had surgery for PD such as deep brain stimulation,
score < 24 on the Mini-Mental Status Examination
(MMSE) [27]; or sensory system pathology affecting
walking or communication (e.g. blindness, deafness). All
volunteers will be screened by a physiotherapist.
Randomisation and blinding
Concealed randomisation will be prepared by an offsite
investigator who is not involved in recruitment, inter-
vention or data collection using a computer generated
random number sequence. Consecutively numbered,
randomly ordered opaque envelopes containing group
allocation in 1:1 ratio will be opened consecutively after
baseline assessment by the physiotherapists implement-
ing the intervention.
Research assistants who enrol participants, and con-
duct pre, post and follow-up assessments will be blinded
to group allocation throughout the study. Participants
will not be informed of group allocation, however they
may become aware of group allocation due to the nature
of the intervention. Participant coding will not refer to
group and participants will be instructed not to divulge
information regarding their intervention to the research
assistants undertaking the assessments. Treating phy-
siotherapists will not be blind to group. To control
expectancy effects for treating physiotherapists and
patients it will be explained that it is not yet determined
which therapy is more effective.
Intervention
Single task training
Participants in the single task control group will participate
in a 12-session program administered for 40-60 minutes
each session, typically undertaken 3 times per week for
4 weeks. The intervention will be performed by a trained
physiotherapist on a one-on-one basis, with training com-
mencing at the patient’s self-reported optimal ‘ON’ period,
often 1 hour post medication. The single task group will
receive an individually-progressed program of gait training
aimed at improving step length via repeated practice of
straight line walking, turning, obstacle negotiation and
challenging gait tasks such as increasing speed and altering
surface challenges. The classes will be performed in a hos-
pital environment. A weekly guide for progression of task
type and difficulty will be used. External cues to increase
step length when walking will be used when needed and
may include verbal, visual or auditory approaches. Partici-
pants will be instructed to concentrate on their walking
performance during training. When training, care will be
taken to ensure instructions are not performed when walk-
ing to avoid dual tasking during this intervention. A home
program will be progressively integrated from week 2 with
participants asked to continue with this program for 6
months. This will include a walking program, and a range
of balance, strengthening and postural exercises particular
to the patient, but chosen from a set of potential exercises.
On completion of the intervention, participants will have a
daily calendar in which to record their home program, and
will receive monthly reminder follow-up telephone calls.
Dual task training
Participants in the dual task training group will also parti-
cipate in a 12-session program administered for 40-60
minutes each session, typically undertaken 3 times per
week for 4 weeks. As per the single task training group,
the intervention will be undertaken by a trained phy-
siotherapist on a one-on-one basis, with training commen-
cing at the patient’s self-reported optimal ‘ON’ period,
often 1 hour post medication. The dual task gait training
program will aim to improve step length under dual task
conditions, that is, when concurrently performing added
cognitive or motor tasks. Participants will undertake
repeated practice of walking aiming to improve step length
using external cueing techniques as outlined above, pro-
gressing to internal concurrent cueing of appropriate step
length. The gait tasks undertaken will be progressed from
simple to more complex tasks as outlined for the single
task group.
In addition, a variety of added tasks will be progres-
sively integrated into the training program. These include
tasks such as listening, speaking, conversing, generation
of simple and complex lists, language, calculation and
motor tasks increasing in complexity. Tasks will include
those designed to reflect functional everyday activities,
such as carrying bags, getting keys out of a pocket, count-
ing money, recalling directions or making a shopping list.
Complexity will be progressively integrated as more com-
plex tasks result in greater dual task interference with
gait in people with PD [17,23,28,29]. Tasks involving
maths and calculation will also be included as added lan-
guage and calculation tasks can differentially impact gait
performance in people with PD [20]. If able, participants
will be progressed to performing increasingly complex
cognitive tasks while concurrently walking. These may
include visual spatial planning tasks (e.g. tell me how to
get from here to reception), response inhibition tasks
(e.g. complete the phrase without saying ...), or tasks inte-
grating both language and calculation components (e.g. if
Saturday is the 8th, what is the date the following Thurs-
day?). Motor tasks such as carrying and manipulation
will also be included as added tasks, as some studies have
reported that added cognitive and motor tasks can both
impact gait performance in people with PD [23]. These
may be combined with cognitive tasks (e.g. getting a
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certain amount of money out of a wallet when walking).
A weekly guide for progression of task type and difficulty
will be used and programs will be individually-
progressed.
Instructional set will commence with fixed priority
training, whereby attention is equally shared between
the walking and added task, but will aim to progress to
variable priority training, whereby the proportion of
attention directed to the gait and added task is varied
from repetition to repetition [30]. For example, on one
walking pass, a participant will be asked to concentrate
mainly on taking big steps when also performing a
counting task. In the next pass, they will be asked to
concentrate mainly on the added task, trying to count as
quickly and accurately as possible. Variable priority
training has been shown to result in better balance dur-
ing dual task gait conditions in older adults with balance
impairment than fixed priority training [30], so this
approach will be gradually introduced.
Outcome measures
The primary outcome measure will be step length when
dual tasking over 8 metres. Reduced step length has
been shown to be one of the primary gait deficits in
people with PD [31]. Participants will walk an unob-
structed 10 metre path over an 8 metre GAITRite® elec-
tronic walkway at a comfortable pace. At the same time,
they will be asked to perform an added spoken task,
including saying as many words as possible beginning
with certain letters, termed the controlled oral word
association test (words), or counting backwards by 3s
beginning with a number between 50 and 100 (count).
Both these tasks have been used to demonstrate altered
gait in people with PD when dual tasking [20,25]. Step
length is calculated by the GAITRite system, with the
mean value used in analysis. The GAITRite® system has
demonstrated sensitivity to change in gait parameters in
people with PD [32] and has been used as a gold stan-
dard comparator when investigating gait under dual task
conditions in people with PD [33]. Assessment will be
performed during the patient’s self-reported optimal
‘ON’ period, often 1 hour post medication.
Secondary outcome measures include: spatiotemporal
gait parameters when walking under single and dual
task conditions, cognitive function, functional gait per-
formance, community mobility, and quality of life. Spa-
tiotemporal gait parameters other than step length will
be recorded when walking at a comfortable pace over
10 metres under both gait only (single task) and the two
dual task conditions detailed previously. These will
include gait speed (m/s), cadence (steps/min), stride
length (m), step length coefficient of variation (CV) and
double support time (s).
Cognitive domains to be tested by a neuropsychologist
include: executive function, attention, visual perception
and processing speed. Tests have been selected based on
their ability to assess the required domains, and their
ability to detect deficits in the Parkinson Disease popu-
lation [34]. Tests include the Trail making A & B Tests
[35]; the Stroop colour-word interference test [36], and
a Digit span test [37].
Functional gait performance will be measured using
the Timed Up and Go (TUG) test with added motor
and cognitive tasks [38]. Participants will be asked to
walk as quickly as they safely can under all conditions
and will be permitted to use their usual gait aid. A six
minute walk test will be completed to quantify walking
capacity. This test has demonstrated high reliability in
people with PD (ICC = 0.95) [39].
Community mobility will be quantified using a ques-
tionnaire based on a self-report tool designed for com-
munity-dwelling older adults [40]. Activity will be
measured over 3 days using an ActivPAL[41]. Health-
related quality of life will be measured using a generic
health-related quality of life measure, the EuroQuol
(EQ-5D) [42] and the PDQ-39, which is specific to the
Parkinson Disease population [43].
Several measures will be taken to characterise partici-
pants at each assessment session. Severity of PD will be
categorised using the Hoehn and Yahr scale [26] and
the Unified Parkinson’s Disease Rating Scale (UPDRS)
motor subsection III [44]. Freezing will be characterised
using the Freezing of Gait questionnaire [45] and confi-
dence will be measured using the ambulatory self confi-
dence questionnaire [46]. General demographic
information to be recorded will include: age, disease
duration, medical history, number of falls in previous
year, mobility aid use, medication type and dosage.
Medication will be documented in detail at every assess-
ment timepoint.
Data analysis
Data analysis will be performed on an intention-to-treat
basis using an alpha level of 0.05. Descriptive statistics will
be used to ensure comparability of scores between groups
at baseline, to describe performance at each phase and to
test whether the assumptions for use of parametric statis-
tics have been met. If the assumptions for F or t-tests are
violated, equivalent non-parametric statistics will be uti-
lized. The main hypothesis will be tested using General
Linear Models (repeated measures analysis of variance,
ANCOVA), in a 2 group (single task, dual-task) × 4 phase
(baseline 1, baseline 2, post intervention, follow up) model.
This will be followed by between-groups planned compari-
sons using the t-statistic. All secondary outcomes will be
analysed in a similar manner. Disease duration and age
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will be used as co-variates in all analyses. Data will be ana-
lysed using SPSS.
Sample size
Large standardized effect sizes (e.g. 0.1-0.5 m stride
length; 10-25 m/min gait speed) shown in previous
experiments where there were 2 active interventions to
improve gait in people with PD using strategy training
[11] (Cohen’s d >5) led to the prediction that a sample
size of 30 in each group will yield power in excess of
99% with a = 0.05 for step length and speed. Previous
studies with similar populations of people with PD
(Morris [11,28,29,31] et al., indicate that attrition is typi-
cally in the range of 5-8%. Even if the sample dimin-
ished by 2 in each group, the power would still exceed
95%.
Ethics approval
The study protocol has been approved by the University of
Queensland Medical Research Ethics Committee (MREC
ID: 2007001631), the Princess Alexandra Hospital Ethics
committee (ID: 2009013), the Uniting Care Health Human
Research Ethics Committee (ID: 0911).
Discussion
This trial will be the first to compare the effect of dual
task training when walking with single task (usual strat-
egy gait training) in people with PD. Currently it is not
clear whether training dual tasking when walking should
be advocated in people with PD. It will measure the
effect on not only gait performance, but also on other
indicators of impairment, activity and participation both
immediately following training, and for a follow up per-
iod of 6 months. This data will assist in determining the
impact of physiotherapy gait training for people with
Parkinson Disease who are still mobile and living in
their own homes. It will be one of the first studies to
monitor the effect of this type of intervention on com-
munity mobility disability in the PD population, and to
determine transference to activities in daily life.
Findings from this study will provide insights into the
effects of practice on dual-task performance in people
with PD. It will generate new knowledge regarding opti-
mal principles of training to enable people with PD to
overcome debilitating dual task interference during
rehabilitation. The information gained from this project
has the potential to change the way gait training is
structured, and will provide clear evidence as to whether
dual task training should be advocated in people with
PD. Our results are likely to have wider implications for
training other populations who commonly demonstrate
dual task interference with postural tasks such as elders
[14,15] and people with brain injuries [16] as it is
expected that the principles underpinning the design of
the training program will be transferable to these
populations.
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